- Home
- WINT vs VMAR Comparison
WINT vs VMAR Comparison
Compare WINT & VMAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- VMAR
- Stock Information
- Founded
- WINT 1992
- VMAR 1995
- Country
- WINT United States
- VMAR Canada
- Employees
- WINT N/A
- VMAR N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- VMAR Marine Transportation
- Sector
- WINT Health Care
- VMAR Industrials
- Exchange
- WINT Nasdaq
- VMAR Nasdaq
- Market Cap
- WINT 2.9M
- VMAR 2.3M
- IPO Year
- WINT 1995
- VMAR 2020
- Fundamental
- Price
- WINT $0.31
- VMAR $1.48
- Analyst Decision
- WINT Hold
- VMAR Strong Buy
- Analyst Count
- WINT 1
- VMAR 1
- Target Price
- WINT $7.00
- VMAR $270.00
- AVG Volume (30 Days)
- WINT 1.2M
- VMAR 720.8K
- Earning Date
- WINT 11-27-2024
- VMAR 01-14-2025
- Dividend Yield
- WINT N/A
- VMAR N/A
- EPS Growth
- WINT N/A
- VMAR N/A
- EPS
- WINT N/A
- VMAR N/A
- Revenue
- WINT N/A
- VMAR $2,811,751.00
- Revenue This Year
- WINT N/A
- VMAR $120.43
- Revenue Next Year
- WINT N/A
- VMAR N/A
- P/E Ratio
- WINT N/A
- VMAR N/A
- Revenue Growth
- WINT N/A
- VMAR N/A
- 52 Week Low
- WINT $0.32
- VMAR $1.30
- 52 Week High
- WINT $14.75
- VMAR $162.00
- Technical
- Relative Strength Index (RSI)
- WINT 28.66
- VMAR 28.47
- Support Level
- WINT $0.33
- VMAR $1.42
- Resistance Level
- WINT $0.42
- VMAR $1.73
- Average True Range (ATR)
- WINT 0.03
- VMAR 0.17
- MACD
- WINT 0.02
- VMAR 0.10
- Stochastic Oscillator
- WINT 1.91
- VMAR 43.40
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About VMAR Vision Marine Technologies Inc.
Vision Marine Technologies Inc is in the business of designing and manufacturing electric outboard powertrain systems, power boats, and related technology and the renting of electric boats. The different models of the powerboats and electric boats manufactured by the company include Bruce 22, Fantail 217, Volt 180, and others. The company operates in two reportable business segments; Sale of electric boats and Rental of electric boats. The majority of the revenue for the company is generated from the Sale of electric boats segment. Geographically, the company generates revenue from its business in Canada, USA and other countries. A substantial portion of the overall revenue is generated from its business in USA.